Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

A phase 3 trial is evaluating ASP-1929 photoimmunotherapy plus Keytruda in first-line treatment for recurrent head and neck ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Research found that ibrutinib reduces red blood cell aggregation in patients with chronic lymphocytic leukemia (CLL), while ...

Scientists have discovered a potential new treatment for familial hypercholesterolemia, inspired by signs seen in the Mona ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed a computer model to help scientists identify tumor-fighting immune cells in ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

A novel approach developed by scientists, including Rice University chemist James Tour, could transform treatment for ...

University of Kentucky Markey Cancer Center researchers have discovered a promising new way to combat therapy-resistant ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

A civil rights attorney said the state agencies named in the lawsuit unfairly targeted health care providers during the ...